Dose-response assessment of the anti-cancer efficacy of soy isoflavones in dimethylhydrazine-treated rats fed 6% fructooligosaccharide
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
We investigated the combinatorial effects of different doses of dietary soy isoflavones (SI) and fructooligosaccharide (FOS) in a rat model of colon cancer. We hypothesized that increased bioavailability of SI metabolites due to dietary FOS may increase production of bioactive equol and affect colon carcinogenesis in a dose-dependent manner. Sprague-Dawley male rats were injected with 12-dimethylhydrazine (DMH) and were provided experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg of diet and 6% FOS for 12 weeks. The number of aberrant crypt foci (ACF) and the expression of cyclooxygenase-2 (COX-2) in colonic tissues were significantly decreased in the 6% FOS-fed groups compared to the control group. Gut transit time and fecal pH were significantly lower, and fecal concentrations of bifidobacteria were increased with 6% FOS. However, dietary SI supplementation in combination with 6% dietary FOS did not affect ACF formation or COX-2 expression. Plasma equol concentrations were dose-dependently increased by supplementation of SI up to 500 mg/kg of diet. In conclusion, SI supplementation up to 500 mg/kg of diet appeared to have no additive beneficial effects in rats with chemically-induced colon cancer that were fed 6% FOS, although plasma equol was dose-dependently increased.
Abstract
We investigated the combinatorial effects of different doses of dietary soy isoflavones (SI) and fructooligosaccharide (FOS) in a rat model of colon cancer. We hypothesized that increased bioavailability of SI metabolites due to dietary FOS may increase production of bioactive equol and affect colon carcinogenesis in a dose-dependent manner. Sprague-Dawley male rats were injected with 12-dimethylhydrazine (DMH) and were provided experimental diets that contained 0, 10, 50, 150, or 500 mg SI per kg of diet and 6% FOS for 12 weeks. The number of aberrant crypt foci (ACF) and the expression of cyclooxygenase-2 (COX-2) in colonic tissues were significantly decreased in the 6% FOS-fed groups compared to the control group. Gut transit time and fecal pH were significantly lower, and fecal concentrations of bifidobacteria were increased with 6% FOS. However, dietary SI supplementation in combination with 6% dietary FOS did not affect ACF formation or COX-2 expression. Plasma equol concentrations were dose-dependently increased by supplementation of SI up to 500 mg/kg of diet. In conclusion, SI supplementation up to 500 mg/kg of diet appeared to have no additive beneficial effects in rats with chemically-induced colon cancer that were fed 6% FOS, although plasma equol was dose-dependently increased.
참고문헌 (33)
- Adlercreutz H, "Phytoestrogens: epidemiology and a possible role in cancer protection", Environ Health Perspect, 103, pp.103~112 (1995)
- American Institute of Nutrition, "Report of the ad hoc committee on standards for nutrition studies", J Nutr, 123, pp.1939~1951 (1993)
- Atkinson C, "In vitro incubation of human feces with daidzein and antibiotics suggests interindividual differences in the bacteria responsible for equol production", J Nutr, 134, pp.596~599 (2004)
- Atkinson C, "Gut bacterial metabolism of soy isoflavone daidzein: Exploring the relevance to human health", Exp Biol Med, 230, pp.155~170 (2005)
- Bird RP, "Role of aberrant crypt foci in understanding the pathogenesis of colon cancer", Cancer Lett, 93, pp.55~71 (1995)
- Bird RP, "The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer", Toxicol Lett, 112-113, pp.395~402 (2000)
- Birt DF, "Dietary agents in cancer prevention: flavonoids and isoflavonoids", Pharmacol Ther, 90, pp.157~177 (2001)
- Brouwers E, "Time-resolved fluoroimmunoassay for equol in plasma and urine", J Steroid Biochem Mol Biol, 84, pp.577~587 (2003)
- 조재위, "Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: p38 MAP kinase and JNK as potential upstream targets", Experimental and Molecular Medicine, 37(3), pp.186~192 (2005), 대한생화학ㆍ분자생물학회
- Cotterchio M, "Dietary phytoestrogen intake is associated with reduced colorectal cancer risk", J Nutr, 136, pp.3046~3053 (2006)
- Cummings JH, "Diet and the prevention of cancer", BMJ, 317, pp.1636~1640 (1998)
- Daly KT, "Enhanced estrogenic responses and sensitivity to azoxymethane following dietary soy isoflavone supplementation in older female rats", Food Chem Toxicol, 45, pp.628~637 (2007)
- Guo JY, "Dietary soy isoflavones and estrone protect ovariectomized ERαKO and wild-type mice from carcinogen-induced colon cancer", J Nutr, 134, pp.179~182 (2004)
- Jacoby RF, "The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis", ancer Res, 60, pp.5040~5044 (2000)
- Ji GE, "Investigation of selective medium for isolation and enumeration of Bacteriodes sp. from the feces of the Korean people", Korean Journal of Food Science and Technology, 26, pp.295~299 (1994)
- Khalil DA, "Soy isoflavones may protect against archidectomy-induced bone loss in aged male rats", Calcif Tissue Int, 76, pp.50~62 (2005)
- Lim CC, "Dietary fibers as prebiotics :implications for colorectal cancer.Mol Nutr Food Res", Mol Nutr Food Res, 49, pp.609~619 (2005)
- McClain RM, "Acute, subchronic and chronic safety studies with genistein in rats", Food Chem Toxicol, 44, pp.56~80 (2006)
- Mathey J, "Fructooligosaccharides maximize bone-sparing effects of soy isoflavoneenriched diet in the ovariectomized rat", Calcif Tissue Int, 75, pp.169~179 (2004)
- Messina M, "Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data", Baillieres Clin Endocrinol Metab, 12, pp.707~728 (1998)
- Nielsen ILF, "Review of the factors affecting bioavailability of soy isoflavones in human", Nutr Cancer, 57, pp.1~10 (2007)
- Ohta A, "A combination of dietary fructooligosaccharides and isoflavone conjugates increases femoral bone mineral density and equol production in ovariectomized mice", J Nutr, 132, pp.2048~2054 (2002)
- Onoue M, "Specific species of intestinal bacteria influence the induction of aberrant crypt foci by 1,2-dimethylhydrazine in rats", Cancer Lett, 113, pp.179~186 (1997)
- Oshima M, "Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase-2 (COX-2)", Cell, 87, pp.803~809 (1996)
- Picherit C, "Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats", J Nutr, 130, pp.1675~1681 (2000)
- Pierre F, "Short-chain fructo-oligosaccharides reduce the occurrence of colon tumors and develop gut-associated lymphoid tissue in Min mice", Cancer Res, 57, pp.225~228 (1997)
- Setchell KDR, "The clinical importance of the metabolite Equol - A clue to the effectiveness of soy and its isoflavones", J Nutr, 132, pp.3577~3584 (2002)
- Sheehan KM, "The relationship between cyclooxygenase-2 expression and colorectal cancer", JAMA, 282, pp.1254~1257 (1999)
- Sorensen IK, "The effect of soy isoflavones on the development of intestinal neoplasia in ApcMin mouse", Cancer Lett, 130, pp.217~225 (1998)
- Hye-Young Sung, "Fructooligosaccharide and Soy Isoflavone Suppress Colonic Aberrant Crypt Foci and Cyclooxygenase-2 Expression in Dimethylhydrazine-Treated Rats", Journal of Medicinal Food, 11(1), pp.78~85 (2008), 한국식품영양과학회
- Young-Sun Choi, "Soy Isoflavones Do Not Alter the Effects of Fructooligosaccharide on the Intestinal Ecosystem of Colon-Cancer Model Rats", Food Science and Biotechnology, 15(6), pp.931~936 (2006), 한국식품과학회
- Uehara M, "Dietary fructooligosaccharides modify intestinal bioavailability of a single dose of genistein and daidzein and affect their urinary excretion and kinetics in blood of rats", J Nutr, 131, pp.787~795 (2001)
- Diet, Nutrition and the Prevention of Chronic Diseases, "WHO", 95~104, pp.Technical Report Series 916 (2003)